The decision to out-license ARV-806 signals a strategic retreat from a high-profile KRAS G12D program, likely viewed negatively by the market given the $499M market cap and 62% analyst bullishness. Monitor for any partnership announcement or further pipeline cuts; cash runway into H2 2028 provides some buffer but does not offset the development setback.
Price Chart
Executive Summary
Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose escalation trial for ARV-806 (KRAS G12D) and then seek an out-licensing partner for further development. The company also furnished an investor presentation for the Jefferies Global Healthcare Conference. Cash runway extends into H2 2028.
Key Facts
- Arvinas is deprioritizing ARV-806, its KRAS G12D program, after completing Phase 1 dose escalation enrollment in Q2 2026.
- The company plans to out-license any further clinical trials (dose expansion or combination) for ARV-806.
- Cash, cash equivalents, and marketable securities as of March 31, 2026 are expected to fund operations into H2 2028.
- An investor presentation was furnished for the Jefferies Global Healthcare Conference on June 3, 2026.
Financial Impact
Pipeline de-prioritization of ARV-806, a key clinical-stage asset, reduces the company's internal development scope and may impair perceived pipeline value. No financial terms of a potential out-license were disclosed.
Risk Factors
- Failure to secure a favorable out-licensing deal for ARV-806 could result in full program write-off.
- Pipeline narrowing increases reliance on remaining programs (e.g., ARV-471, ARV-110), heightening binary risk.
- Cash burn rate may accelerate if no partnership income materializes, potentially requiring dilutive financing before H2 2028.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-039818 |
| Document: 0001628280-26-039818-index-headers.html | 0001628280-26-039818 |
| Document: 0001628280-26-039818-index.html | 0001628280-26-039818 |
| Document: 0001628280-26-039818.txt | 0001628280-26-039818 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 144 | $9.08 $8.26 | ▼ −9.03% | ▼ −7.91% | $7.41 (−18.39%) |
Jun 22, 2026 14w ago | 8-K | $8.14 $8.29 | ▲ +1.84% | ▲ +0.83% | $7.41 (−8.97%) |
Jun 2, 2026 17w ago | 8-K | $7.70 $6.98 | ▲ +9.35% | ▲ +5.53% | $7.41 (+3.77%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | Press Release | $9.57 $8.78 | ▲ +8.26% | ▲ +8.33% | $7.41 (+22.57%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 5, 2026 21w ago | Press Release | $10.61 $9.57 | ▲ +9.80% | ▲ +11.79% | $7.41 (+30.16%) |
May 1, 2026 22w ago | 8-K | $10.51 $10.19 | ▼ −3.04% | ▼ −5.39% | $7.41 (−29.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access